NSCLC metastatic/no molecular target

Ongoing protocols: click on the protocol for the inclusion and exclusion criteria (update 17/11/2022)

1st line
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

PDC-LUNG-101 (PDC*line)
Safety, Immunogenicity and Preliminary Clinical Activity Study of  PDC*Lung01 Cancer Vaccine in NSCLC.
(cohort B2 open)

2nd line 
Sasanlimab (Pfizer)
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer.

CARMEN-LC03 (Sanofi) (after chemo- and immunotherapy)
SAR408701 (tusamitamab ravtansine; ADC) Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients.

ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

3rd line
ImmunoSABR (Academic)
Combination of SABR plus L19-IL2 in Patients With Stage IV Lung Cancer in addition to standard of care.

2nd-3rd-4th line

CARMEN-LC06 (Sanofi)
Open label, Phase 2 study, evaluating the efficacy and safety of tusamitamab ravtansine (ADC) in participants with CEACAM5 negative-moderate expression and high circulating CEA non-squamous non-small-cell lung cancer (NSQ NSCLC).